Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway

Dennis Y. Chuang  
*University of Missouri*

Agnes Simonyi  
*University of Missouri*

Paul T. Kotzbauer  
*Washington University School of Medicine in St. Louis*

Zezong Gu  
*University of Missouri*

Grace Y. Sun  
*University of Missouri*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**
Chuang, Dennis Y.; Simonyi, Agnes; Kotzbauer, Paul T.; Gu, Zezong; and Sun, Grace Y., "Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway." *Journal of Neuroinflammation*. 12, 199. (2015).  
[https://digitalcommons.wustl.edu/open_access_pubs/4751](https://digitalcommons.wustl.edu/open_access_pubs/4751)
Cytosolic phospholipase A$_2$ plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway

Dennis Y. Chuang$^{1,2,3}$, Agnes Simonyi$^{2,3,4}$, Paul T. Kotzbauer$^5$, Zezong Gu$^{1,2,3,6}$ and Grace Y. Sun$^{1,2,3,4}$*

Abstract

Background: Oxidative stress and inflammation are important factors contributing to the pathophysiology of numerous neurological disorders, including Alzheimer’s disease, Parkinson’s disease, acute stroke, and infections of the brain. There is well-established evidence that proinflammatory cytokines and glutamate, as well as reactive oxygen species (ROS) and nitric oxide (NO), are produced upon microglia activation, and these are important factors contributing to inflammatory responses and cytotoxic damage to surrounding neurons and neighboring cells. Microglial cells express relatively high levels of cytosolic phospholipase A$_2$ (cPLA$_2$), an enzyme known to regulate membrane phospholipid homeostasis and release of arachidonic acid (AA) for synthesis of eicosanoids. The goal for this study is to elucidate the role of cPLA$_2$ in mediating the oxidative and inflammatory responses in microglial cells.

Methods: Experiments involved primary microglia cells isolated from transgenic mice deficient in cPLA$_2$$^\alpha$ or iPLA$_2$$^\beta$, as well as murine immortalized BV-2 microglial cells. Inhibitors of cPLA$_2$/iPLA$_2$/cyclooxygenase (COX)/lipoxygenase (LOX) were used in BV-2 microglial cell line. siRNA transfection was employed to knockdown cPLA$_2$ expression in BV-2 cells. Griess reaction protocol was used to determine NO concentration, and CM-H$_2$DCF-DA was used to detect ROS production in primary microglia and BV-2 cells. WST-1 assay was used to assess cell viability. Western blotting was used to assess protein expression levels. Immunocytochemical staining for phalloidin against F-actin was used to demonstrate cell morphology.

Results: In both primary and BV-2 microglial cells, stimulation with lipopolysaccharide (LPS) or interferon gamma (IFN$^\gamma$) resulted in a time-dependent increase in phosphorylation of cPLA$_2$ together with ERK1/2. In BV-2 cells, LPS- and IFN$^\gamma$-induced ROS and NO production was inhibited by arachidonyl trifluoromethyl ketone (AACOCF$_3$) and pyrrophenone as well as RNA interference, but not BEL, suggesting a link between cPLA$_2$ and not iPLA$_2$, on LPS/IFN$^\gamma$-induced nitrosative and oxidative stress in microglial cells. Primary microglial cells isolated from cPLA$_2$$^\alpha$-deficient mice generated significantly less NO and ROS as compared with the wild-type mice. Microglia isolated from iPLA$_2$$^\beta$-deficient mice did not show a decrease in LPS-induced NO and ROS production. LPS/IFN$^\gamma$ induced morphological changes in primary microglia, and these changes were mitigated by AACOCF$_3$. Interestingly, despite that LPS and IFN$^\gamma$ induced an increase in phospho-cPLA$_2$ and prostaglandin E$_2$ (PGE$_2$) release, LPS- and IFN$^\gamma$-induced NO and ROS production were not altered by the COX-1/2 inhibitor but were suppressed by the LOX-12 and LOX-15 inhibitors instead.

(Continued on next page)

* Correspondence: sung@missouri.edu

1 Interdisciplinary Neuroscience Program, University of Missouri, Columbia, MO, USA

2 Center for Translational Neuroscience, University of Missouri, Columbia, MO, USA

Full list of author information is available at the end of the article

© 2015 Chuang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Conclusions: In summary, the results in this study demonstrated the role of cPLA₂ in microglial activation with metabolic links to oxidative and inflammatory responses, and this was in part regulated by the AA metabolic pathways, namely the LOXs. Further studies with targeted inhibition of cPLA₂/LOX in microglia during neuroinflammatory conditions can be valuable to investigate the therapeutic potential in ameliorating neurological disease pathology.

Keywords: Microglia, cPLA₂, Arachidonic acid, Lipoygenase, ROS, NO

Background

Neuroinflammation plays a major role in the progression of neurodegenerative diseases including Alzheimer’s disease, Parkinson’s diseases, cerebral vascular stroke, and infectious HIV encephalopathy. Microglial cells, the resident innate immune cells in the central nervous system (CNS), are known to exert multiple physiologic functions in the brain, including anchoring CNS innate immune response through phagocytosis of foreign pathogens, removing cellular breakdown products, stimulating tissue repair process, and maintaining tissue homeostasis [1]. Activation of microglial cells can also exert significant impact on the propagation of inflammatory responses [2, 3]. For instance, activated microglia was shown in vivo to contribute to expansion of infarct after focal cerebral ischemia [4], and inhibition of microglial activation was proven a viable strategy to prevent inflammatory neuronal death in vitro [5]. Recent studies have placed much focus on the differential functions of polarized M1/M2 microglial cells after activation. While much research is currently underway to distinguish the biochemical and functional properties of each phenotype, most tend to agree that M1 microglia are more cytotoxic and persist during the disease effector stage, whereas M2 microglia are more neuroprotective and predominate during the repair stage [6–8]. The discovery of functional differences and delineation of time course of microglia polarization has generated interest in ways to limit M1 activation and stimulate M2 transformation in order to ameliorate outcomes of neurological diseases, including experimental stroke and traumatic brain injury [9–13].

Biochemically, M1 microglial activation is associated with the release of ROS, NO, glutamate, cytokines (such as TNFα), phospholipases, matrix metalloproteases, and other proinflammatory factors contributing to the progressive neuronal damage observed in many neurodegenerative disorders [14–16]. Therefore, suppressing or limiting microglial activation can have beneficial effects for preventing neuroinflammation and neurodegeneration. Microglia in vitro can be activated with a variety of agents, such as proinflammatory cytokines (TNFα, IL-1β, IFNγ), lipopolysaccharides (LPS), and oligomeric beta amyloid (Aβ) [17]. Studies including those from our laboratory have demonstrated that microglial activation by proinflammatory cytokines and LPS causes induction of iNOS and activation of NADPH oxidase, leading to increased oxidative/nitrosative stress [18].

Phospholipase A₂’s (PLA₂’s) are groups of enzymes that hydrolyze the fatty acids from the sn-2 position of membrane phospholipids. Among the PLA₂’s identified, cPLA₂ and iPLA₂ are the constitutively active PLA₂’s that serve as important mediators for the release of polyunsaturated fatty acids, including arachidonic acid (AA) and docosahexaenoic acid from membrane phospholipids [19, 20]. Multiple studies have demonstrated group IV PLA₂α (cPLA₂α) to be the major PLA₂ responsible for the release of AA and to play an essential role in inflammation. Transgenic mice lacking cPLA₂α have been shown to display significantly reduced deleterious phenotypes in inflammatory diseases, such as ischemic brain injury, anaphylaxis, arthritis, alcoholism, and acute lung injury [21–27]. More recent in vivo studies demonstrated ability for pharmacological inhibitors of cPLA₂ to ameliorate ischemic stroke, experimental autoimmune encephalitis, and spinal cord injury [28–30]. Although cPLA₂ activation in the brain is associated with oxidative stress, neuronal excitation, and neuroinflammation [31], little is known about mechanism(s) for its activation in microglial cells [32]. Previous studies demonstrated protective effects of cPLA₂ inhibition against microglia-induced white matter damage in vivo and oligodendrocyte cell death in vitro, suggesting the role of this enzyme as a potential target to suppress microglia-induced secondary damage in the central nervous system [30]. However, the mode of action of cPLA₂ and its link to the inflammatory responses in microglial cells have not been elucidated in detail. In this study, we isolated primary microglial cells from cPLA₂ and iPLA₂ KO mice to demonstrate the role of cPLA₂ (and not iPLA₂) in mediating oxidative and inflammatory responses from LPS and IFNy stimulation. In addition, we further suggested a mechanism that links cPLA₂-mediated eicosanoid production with downstream ROS and NO generation inBV-2 microglial cells.

Methods

Materials

Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin, and 0.25 % (w/v) trypsin/EDTA were obtained from GibCO (Gaithersburg, MD). Endotoxin-free
fetal bovine serum was from Atlanta Biologicals (Lawrenceville, GA). Lipopolysaccharide (LPS) (rough strains) from Escherichia coli F583 (Rd mutant) was purchased from Sigma-Aldrich (St. Louis, MO). Interferon-γ (IFNy) was purchased from R&D Systems (Minneapolis, MN). Pharmacological inhibitors used included the following: U0126, SB202190, and SP600125 were from Cell Signaling (Beverly, MA). Arachidonyl trifluoromethyl ketone (AACOCF3), pyrophenone, racemic bromoanol lactone (BEL), nordihydroguaiaretic acid (NDGA), ibuprofen, zileuton, and PD146176 were from Cayman Chemical (Ann Arbor, MI). NCTT-956 was from Sigma-Aldrich (St. Louis, MO). RNA interference Lipofectamine RNAiMAX Transfection Reagent was from Life Technologies (Carlsbad, CA). siRNA against cPLA2 Mm_Pla2g4a_8 FlexiTube siRNA (NM_008869) and AllStars Negative Control siRNA were purchased from Qiagen (Hilden, Germany). Antibodies used for Western blots include the following: goat anti-rabbit IgG-horseradish peroxidase, goat anti-mouse IgG-horseradish peroxidase, anti-cPLA2 rabbit polyclonal, anti-iNOS rabbit polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA); monoclonal anti-β-actin peroxidase (Sigma-Aldrich, St. Louis, MO); rabbit polyclonal anti-p-cPLA2, rabbit polyclonal anti-ERK1/2, and mouse monoclonal anti-phospho-ERK1/2 antibodies (Cell Signaling, Beverly, MA). An affinity-purified antibody directed against an iPLA2 β peptide corresponding to residues 277–295 was a gift of Drs. Chris Jenkins and Richard Gross (Washington University School of Medicine, St. Louis, MO) [33]. For immunocytochemical staining, rabbit anti-ionized calcium-binding adapter molecule 1 (Iba-1) antibodies (019–19741) was purchased from Wako BioProducts (Richmond, VA), Alexa Fluor 488® phalloidin from Life Technologies (Carlsbad, CA), and 4′,6-diamidino-2-phenylindole (DAPI) from Roche Molecular Chemicals (Basel, Switzerland). For ROS detection, CM-H2DCF-DA (DCF) was purchased from Invitrogen, Inc. (Eugene, OR). WST-1 assay was purchased from Clontech (Mountain View, CA). Prostaglandin E2 (PGE2) ELISA Kit was purchased from Cayman Chemicals (Ann Arbor, MI).

**cPLA2 transgenic animal breeding and genotyping**

All animal care and experimental protocols were carried out in accordance with NIH guidelines and with permission from the University of Missouri Animal Care and Use Committee (protocol #6728). Pairs of C57Bl/6 male and female heterozygous cPLA2+/- mice were kindly provided by Dr Joseph V. Bonventre (Harvard Medical School, Boston, MA) and colony was expanded at the University of Missouri for more than five generations prior to start of the experiments. Wild-type cPLA2+/+ and homozygous knockout cPLA2−/− mice used in the experiments were generated by crossing male and female heterozygous cPLA2+/- mice, and genotyping of litters was done between postnatal day 3–6 by polymerase chain reaction (PCR) as previously described [21].

**iPLA2 transgenic animal breeding and genotyping**

iPLA2β-KO mice were housed and cared for in animal facilities administered through the Washington University Division of Comparative Medicine, and animal procedures were performed according to a protocol approved by the Washington University Animal Studies Committee. iPLA2β-KO mice were previously generated by insertion of the neomycin resistance gene into exon 9 of the mouse iPLA2β (Pla2g6) gene by homologous recombination [34, 35]. KO and WT mice were generated by mating heterozygous mice, and their genotype was determined by a PCR assay. The primers used for PCR genotyping were WT F1 (TTACCCTCGCTTCTCCCTCATG GAGCT), Neo F1 (GGGAACTTCTGACTAGGGGAG GAGTAGAA), and WT R1 (TCTGTTCCTCTAGA GACCCATGGGGCCTT), which when combined in a single PCR reaction generate a 158-bp band for the WT allele and a 254-bp band for the KO allele.

**Primary microglia isolation**

Preparations of primary microglial cells with postnatal day 7–10 C57Bl/6 pups were accomplished with the Miltenyi Biotec MACS cell separation system (Bergisch Gladbach, Germany). Briefly, brains from the genotyped pups were dissected and meninges removed. Tissues were dissociated using the Neural Tissue Dissection Kit (P) (Miltenyi Biotec) with the gentleMACS dissociator. Prior to isolation, cell concentration in the suspension was counted and roughly 10^5 cells were collected for flow cytometry analysis by the Cellular Immunology Core in the University of Missouri. Microglia were isolated from the single-cell suspension using the magnetic activated cell sorting (MACS) technology with anti-cluster of differentiation molecule 11b (CD11b) (Microglia) MicroBeads (Miltenyi Biotec) in combination with an OctoMACS Separator with slight modifications to the manufacturer’s instructions. The number of cells post-isolation was counted, and roughly 10^5 cells were collected for post-isolation flow cytometry analysis, and the remaining cells were plated at a density of 5 × 10^3/cm^2. Plated cells were cultured in DMEM supplemented with 10% FBS containing 100 units/mL penicillin and 100 μg/mL streptomycin and maintained in 5% CO₂ incubator at 37 °C. Culture medium was replaced every 3–5 days. Primary cell cultures were used between days-in-vitro (DIV)5–7.

**Immortalized microglial BV-2 cell culture**

The murine BV-2 cell line was generated by infecting primary microglia cell cultures with a v-raf/v-myc oncogene-carrying retrovirus (J2) [36]. These cells were...
Flow cytometry for microglial cell purity analysis
During primary microglia isolation, after tissue dissociation and cell number were determined, roughly 10^5 cells were collected, resuspended in 100 μL buffer, and incubated with 10 μL CD11b-fluorescein isothiocyanate (FITC) antibodies (Miltenyi) for 10 min in 4 °C. Cells were then washed and resuspended in 100 μL fresh buffer for flow cytometry analysis. Similarly, after microglia isolating by CD11b cell sorting, 10^5 cells were collected and labeled with cd11b-FITC for flow cytometry analysis. Flow cytometry analysis was performed using the BD FACScan under the FITC protocol by the Cellular Immunology Core in the University of Missouri.

cPLA2 RNA interference knockdown in BV-2 cells
BV-2 cells were seeded in 96- and 24-well plates with antibiotic-free DMEM containing 5 % FBS for 24 h. When cell density reached roughly 70–80 %, they were transfected with either AllStars negative control siRNA (Qiagen) or cPLA2 siRNA (NM_008869, Qiagen) (final concentration of 40 nM) using the RNAiMAX transfection reagent (Invitrogen) in mixture of Opti-MEM and DMEM mediums for 48 h prior to being used for experiments, according to the manufacturer's instructions. cPLA2 knockdown was evaluated by Western blot for protein expression of total cPLA2 normalized against β-actin.

Cell viability assay protocol
The WST-1 protocol was used for assessment of cell viability. Briefly, after reaching 80–90 % confluence, cells in 96-well plates were serum starved for 4 h, followed by incubation with inhibitors for 1 h. After treatment, cell viability was determined by adding 10 μL of the WST-1 reagent (Roche Applied Science, Germany) to each well. After gentle shaking, cells were incubated for 1 h at 37 °C and absorbance was read at 450 nm (with reference wavelength at 650 nm).

NO determination
NO released from BV-2 cells was converted to nitrite in the culture medium. NO concentration was measured using the Griess reagent protocol as described previously [18]. In brief, BV-2 cells in 96-well plate were serum starved in phenol red-free DMEM for 3 h, followed by incubation with designated inhibitors for 1 h. Cell were then incubated with IFNγ or LPS at 37 °C for 16 h. Alternatively, primary microglia were stimulated with IFNγ or LPS at 37 °C for 24/48 h. Aliquots of medium (50 μL) were incubated with 50 μL of the reagent A [1 % (w/v) sulfanilamide in 5 % phosphoric acid, Sigma-Aldrich] for 10 min at room temperature covered in dark. This was followed by addition of 50 μL of reagent B [0.1 %, w/v, N-1-naphthylethylendiamine dihydrochloride, Sigma-Aldrich] for 10 min at room temperature, protected from light, and absorbance at 543 nm was measured using a microplate reader (Biotek Synergy 4, Winooski, VT). Serial dilutions of sodium nitrite (0–100 μM) were used to generate the nitrite standard curve.

ROS determination
ROS production in microglial cells was assessed with 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCF-DA, or DCF in short). Primary microglia or BV-2 microglial cells were seeded in 96-well plate and grown until 90 % confluent. Cells were serum starved for 3 h, followed by pretreatment with inhibitors for 1 h, prior to stimulation with LPS or IFNγ for 1 h. Alternatively, primary microglia were stimulated with IFNγ or LPS at 37 °C for 24/48 h. DCF (10 μM) was added to each well and incubated for 1 h. The fluorescent intensity of DCF was measured with a microplate reader (excitation wavelength of 490 nm and emission wavelength of 520 nm). Fluorescent intensity was normalized against control wells for statistical analysis.

PGE2 ELISA protocol
PGE2 concentration in the cell-conditioned medium was assessed with the PGE2 ELISA protocol (Cayman Chemicals). Briefly, 50 μL of conditioned medium from treated BV-2 cells in 96-well plates were incubated with 50 μL of PGE2 monoclonal antibody and 50 μL of PGE2 AChE tracer for 18 h at 4 °C with plate covered with plastic film. Standard curve was generated with serial dilution of PGE2 ELISA standard (Cayman No. 414014) in EIA buffer prepared according to Cayman's protocol. On day 2, 100 μL of Ellman's Reagent was reconstituted with 20 mL of UltraPure water and 200 μL added into each sample/standard well for development. The plate was placed on an orbital shaker for 60 min prior to measuring for absorbance at 410 nm using a microplate reader. Concentration was calculated from the fourth-degree polynomial
Western blot analysis
Cell lysates were collected in RIPA buffer containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, and 0.1% SDS. The extract was centrifuged at 10,000×g for 15 min at 4 °C and transferred to a clean tube to remove cell debris. Protein concentration was measured and normalized with the BCA protein assay kit (Pierce Biotechnology, Rockford, IL). Depending on the target of interest, 5–10 μg of total protein was loaded in SDS-PAGE for electrophoresis. After electrophoresis, proteins were transferred to 0.45-μm nitrocellulose membranes. Membranes were incubated in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and 5% non-fat milk for 1 h at room temperature. The blots were incubated at 4 °C overnight with antibodies cPLA2 (1:1000), phospho-cPLA2 (1:1000), ERK1/2 (1:2000), phospho-ERK1/2 (1:1000), iNOS polyclonal (1:1000), and β-actin (1:50,000). After repeated washing with 1X TBS-T, blots were incubated with goat anti-rabbit IgG-HRP (1:4000) or goat anti-mouse IgG-HRP (1:2000) for 1 h at room temperature. Immunolabeling was detected by chemiluminescence ECL/WestPico/Femto and developed in X-ray film developer. Films were scanned, and the optical density of bands was measured with the QuantityOne software (BioRad, Hercules, CA).

Immunocytochemistry staining
Immunocytochemistry staining was carried out as previously described by Chuang et al. [39]. Briefly, cells were cultured in 24-well plates containing round cover slips. After treatment, cells were fixed in 4% paraformaldehyde for 15 min and then permeabilized with 0.1% Triton X-100 in PBS for 30 min. Cells were incubated with 10% normal goat serum in 0.005% Triton X-100 in PBS for 60 min then incubated overnight in 0.5% normal goat serum in 0.005% Triton X-100 in PBS containing primary antibodies. The next day, cells were incubated in 0.005% Triton X-100 in PBS containing secondary antibodies, goat-anti-rabbit Alexa fluor 488 (Jackson Immunoresearch), and goat-anti-mouse Alexa fluor 549 (Jackson Immunoresearch) for 60 min, followed by 1 unit of Alexa Fluor 488 phalloidin (Life Technologies)/well for 20 min (5 μL of 6.6 μM stock solution dissolved in methanol diluted to 200 μL of 0.005% Triton X-100 in PBS), and nuclear counterstaining with 1 μg/mL of 4,6-diamidine-2-phenylindole dihydrochloride (DAPI) (Pierce) in PBS for 10 min. The coverslips were then mounted on fluoromount (Sigma-Aldrich) and sealed with nail polish. Fluorescence photomicrographs were captured using a Leica DMI 6000B fully automated epifluorescence microscope (Leica Microsystems Inc., Buffalo Grove, IL).

Statistical analysis
Data were presented as means ± SEM. Results were analyzed either by one-way ANOVA followed by Dunnett’s multiple comparison tests (V4.00; GraphPad Prism Software Inc., San Diego, CA). Statistical significance was considered for P < 0.05.

Results
Stimulation of iNOS, p-ERK1/2, and p-cPLA2 protein expression by LPS and IFNγ in primary and immortalized (BV-2) microglial cells
In this study, we first characterized primary microglial cells isolated from 7–10 days postnatal c57bl/6 WT and cPLA2 KO mouse brains using the Miltenyi Biotec MACS protocol. Flow cytometry analysis showed 14% of cells from the homogenized brain tissues to express CD11b surface antigen (microglia) prior to cell sorting/isolation (Fig. 1a). After MACS isolation, more than 90% of isolated cells were CD11b positive, indicating relatively high purity from the isolation protocol (Fig. 1b). Immunocytochemistry staining with antibodies targeted against CD11b followed by fluorescent microscopy demonstrated staining in nearly all cells with morphology that resembled ramified microglial cells (Fig. 1c).

Our earlier studies have demonstrated the ability for BV-2 microglial cells to upregulate iNOS and produce NO after LPS or IFNγ stimulation individually and proposed ERK1/2 as one of the central components in mediating this transcriptional process [39, 40]. In this study, a time course study was carried out to test induction of iNOS, p-ERK1/2, and p-cPLA2 by LPS and IFNγ using primary cells and compare with BV-2 microglial cells. When primary microglial cells were stimulated with LPS (200 ng/mL), ERK1/2 was phosphorylated within an hour and started to decline after 2 h albeit remaining elevated up to 24 h compared with baseline (Fig. 2a). Following the increase in pERK1/2, LPS also induced increase in cPLA2 phosphorylation, with maximal expression occurring at 4 h prior to a gradual decline (Fig. 2a). On the other hand, iNOS expression was not observed until after 8 h and was highest at 24 h (Fig. 2a). A similar expression profile was observed when primary microglia was stimulated with IFNγ (20 ng/mL), although the sequence of events appeared to be delayed with ERK1/2 phosphorylation maxing at 4 h, cPLA2 phosphorylation maxing at 8 h, and iNOS expression not observed until 16 h post-stimulation (Fig. 2b). With IFNγ, p-cPLA2 remained upregulated at 24 h post-stimulation. There were no significant changes in total ERK1/2 or cPLA2 protein during the activation process. When the same conditions were subjected to BV-2 cells,
Fig. 1 (See legend on next page.)
matching trends were observed among the proteins of interest (Fig. 2c, d), with exception that LPS stimulation of p-ERK1/2 and p-cPLA2 appeared to be stronger than the primary microglial cells and remained upregulated at 24 h. These results suggest the use of BV-2 cells as a justified model system to investigate biochemical profiles of our pathway of interest during microglial activation.

cPLA2 phosphorylation is regulated by phospho-ERK1/2
Among multiple sites, Ser505 residue is the site phosphorylated by MAPKs in cPLA2 [41]. In this study, we examined the effects of MAPK inhibitors, U0126 (MEK1/2-ERK1/2 inhibitor), SB202190 (p38 MAPK inhibitor), and SP600125 (JNK inhibitor) on cPLA2 phosphorylation after stimulation by LPS at 2 h post-stimulation and by IFNγ at 8 h post-stimulation in BV-2 cells. Results demonstrated that among the inhibitors tested, U0126 inhibited Ser505 phosphorylation in a dose-dependent manner whereas SB202190 and SP600125 were not effective (Fig. 3a, c). Similar results were observed with IFNγ (Fig. 3b, d). These results are consistent with the notion that phospho-ERK1/2 serves as the primary regulator of cPLA2 phosphorylation in microglia cells.

LPS- and IFNγ-induced iNOS expression and NO production are significantly decreased in microglia deficient in cPLA2
In this study, primary microglial cells isolated from WT and cPLA2−/− homozygous KO mice brains were used to test for their ability to induce iNOS expression and NO production upon stimulation with LPS or IFNγ. As expected, cPLA2 expression was blunted in microglia isolated from the cPLA2 KO brain as compared to the WT brain (Fig. 4a). Under the same conditions, LPS-induced iNOS expression and NO production were significantly decreased in microglia isolated from the cPLA2 KO brain as compared to the WT brain (Fig. 4a, b, d). Similarly, IFNγ-induced iNOS expression and NO production were also significantly decreased in microglial cells from the cPLA2 KO brains (Fig. 4a, c, d). The concentration of LPS and IFNγ used in our experiment was shown not to cause significant cell death at the given time points (Additional file 1: Figure S1).
LPS- and IFNγ-induced ROS from WT and cPLA2 KO microglia

Our earlier study demonstrated the temporal profile and mechanism for LPS and IFNγ to induce ROS production in BV-2 microglial cells [39]. In this study, we attempted to compare ROS production between primary microglia isolated from WT and cPLA2 KO brains. In WT primary microglial cells, ROS production was maximally increased after stimulation with 200 ng/mL LPS and continued to increase for 48 h (Fig. 5a). ROS induced by IFNγ was not significantly increased at 24 h but continued to rise at 48 h (Fig. 5b). Under the same conditions and stimulus concentrations, neither LPS nor IFNγ managed to cause significant increase in ROS production in primary microglia isolated from cPLA2 KO brain (Fig. 5c, d).

Pharmacological inhibition and siRNA of cPLA2 result in suppression of LPS- and IFNγ-induced NO production in BV-2 cells

Based on the above data suggesting a link between cPLA2 and LPS/IFNγ-induced NO production, we further tested whether inhibition of cPLA2 by pharmacological inhibitors and by siRNA knockdown may alter the ability for LPS and IFNγ to stimulate NO in BV-2 microglial cells. In this study, two pharmacological inhibitors were used: AACOCF3, a non-specific PLA2 inhibitor known to suppress activity of both cPLA2 and iPLA2, and pyrophenone, a specific cPLA2 inhibitor. As shown in Fig. 6a–d, both inhibitors showed dose-dependent suppression of NO generation 16 h after LPS and IFNγ stimulation. The doses of AACOCF3 and pyrophenone used in this study were verified to not cause toxicity in the culture system using the WST-1 assay while aiming for reasonable level for maximum effect (data not shown).

RNA interference was further employed to ensure the inhibition observed above was not resulted from non-specific pharmacological effects. Using the cPLA2 siRNA (NM_008869, Qiagen) and RNAiMAX transfection reagent, we were able to knockdown cPLA2 by 70–80 %, based on protein expression by Western blot (Additional file 2: Figure S2). Under this condition, NO production was significantly suppressed in knockdown cultures as compared with control cultures (Fig. 6e, f).

Pharmacological inhibition and siRNA of cPLA2 result in significant suppression of LPS- and IFNγ-induced ROS production in BV-2 cells

Our previous study demonstrated that ROS production from NADPH oxidase activation plays a major role in
microglia activation and it precedes iNOS induction and NO production (Chuang et al. 2013). In this study, cPLA₂ inhibitors and siRNA were used to test the link between cPLA₂ and LPS- or IFNγ-induced ROS production in BV-2 cells. As shown in Fig. 7a–d, both AACOCF3 and pyrrophenone dose-dependently inhibited LPS- or IFNγ-induced ROS production where measured at 12 h post-stimulation. Similarly, siRNA also significantly diminished ROS induction by the two stimuli (Fig. 7e, f).
cPLA₂ inhibition prevents morphological changes associated with activation in primary microglia

In order to visualize the morphological changes of microglia under activation by LPS or IFNγ, primary microglia were cultured in coverslips, followed by fixation and immunostaining with Iba-1 (red), marker for microglial cells and phalloidin (green) for actin filaments. Undisturbed microglia cells were uniform in size and displayed small round cytoplasm with an off-centered nucleus, resembling the resting ramified phenotype (Fig. 8a, b). At 24 h after LPS stimulation, there was obvious expansion of cytoplasmic space with significant formation of filopodia (Fig. 8c, d). Cells treated with IFNγ appeared to show higher Iba1 staining with cytoplasm more spread out like a fried egg. Some also showed extensive budding around the periphery (Fig. 8e, f). There were also increased mitotic events as evident by cells with di-nuclei in both types of stimulation. Interestingly, microglia pretreated with 5 µM of AACOCF3 for 1 h prior to LPS or IFNγ stimulation showed preservation of morphology resembling closely to unstimulated ramified microglia in the control plates (Fig. 8g–j).

Ca²⁺-independent PLA₂ does not alter LPS- and IFNγ-induced iNOS/NO/ROS production

cPLA₂ and iPLA₂ are both constitutively expressed in most cell types, and are both possible contributors to AA production along with its downstream cascade. While we had established cPLA₂ to play crucial role in microglia activation, it is also important to investigate whether iPLA₂ may also play a role in this process. Using the Miltenyi Biotec MACS cell separation system, primary microglial cells were isolated from WT and iPLA₂ KO brains. As shown in Fig. 9a, expression of iPLA₂ was not observed in the iPLA₂ KO brains, and stimulation with LPS did not result in a significant difference in iNOS expression and NO production between WT and KO microglia (Fig. 9b, c).

To further verify the results, we also tested whether selective iPLA₂ inhibitor BEL (racemic) may have an effect on LPS- and IFNγ-induced NO and ROS production in BV-2 cells. As shown in Fig. 9d–g, results indicated that BEL did not significantly affect the amount of NO or ROS produced by either stimulus.
cPLA₂-dependent induction of NO or ROS in microglia does not go through COX-1/2

cPLA₂ is responsible for AA production and downstream eicosanoid production. AA can be converted by COX-1/2 into prostaglandin H2 which is further metabolized to prostaglandins, prostacyclin, and thromboxanes. Alternatively, AA can also go through the lipooxygenase (LOX) pathway to generate 5/12/15-hydroperoxyeicosatetraenoic acid (HPETE). COX-1/2 and prostaglandins have always been implicated in inflammatory processes and COX-1/2 remains a popular target of anti-inflammatory therapy by non-steroidal anti-inflammatory drugs (NSAIDs). In the following experiments, we tested the involvement of COX-1/2 in NO/ROS production in BV-2 cells. Using the ELISA protocol, we measured the concentration of PGE₂ in conditioned medium of BV-2 microglial cell cultures after stimulation with LPS or IFNγ. We further investigated the effect of ibuprofen, a non-selective reversible COX-1/2 inhibitor, to inhibit PGE₂ production. Results showed a dose-dependent inhibition of LPS- and IFNγ-induced PGE₂ by ibuprofen (Fig. 10a, b). We further tested whether ibuprofen could inhibit NO and ROS production (Fig. 10c–f).

LOX inhibition significantly suppresses cPLA₂-dependent microglial induction of ROS and NO
cPLA₂-induced AA release can be metabolized by either COX or LOX. Since the above results indicated that

![Fig. 6](https://example.com/figure6.png)

**Fig. 6** NO production in BV-2 cells after LPS or IFNγ stimulation was inhibited by cPLA₂ pharmacological inhibitors or siRNA knockdown. BV-2 cells were starved for 4 h in serum-free DMEM. One hour prior to stimulation, cells were pretreated with the indicated concentrations of cPLA₂ inhibitors: a, b AACOCF₃ or c, d pyrophenone. Cells were then stimulated with a, c 200 ng/mL LPS or b, d 20 ng/mL IFNγ. Alternatively, BV-2 cells were transfected with siRNA against cPLA₂ for 24 h before being stimulated with e 200 ng/mL LPS or f 20 ng/mL IFNγ. For all experiments, conditioned mediums were collected 16 h post-stimulation and NO concentrations were measured by Griess protocol as described in the text. Results were expressed as the mean ± SEM (n=3) and significant difference between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests, **P<0.01; ***P<0.001.
COX played a minimal role in ROS/NO production, experiments were directed to test whether the LOX pathways may mediate LPS- and IFNγ-induced ROS and NO production. The LOX products have been shown to provide an important role in mediating the downstream inflammatory leukotrienes in neurodegenerative conditions and infectious processes [42]. When BV-2 cells were pretreated with NDGA, a non-selective LOX inhibitor, NO and ROS production was significantly suppressed in a dose-dependent manner (Fig. 11a–d).

Among the lipoxygenases, LOX-5, LOX-12, and LOX-15 are the most studied and are responsible for the generation of 5-HPETE, 12-HPETE, and 15-HPETE, respectively. To further investigate which LOX and its subsequent products were responsible for LPS- or IFNγ-induced ROS and NO production in microglia, we incorporated the use of zileuton, NCTT-956, and PD146176, previously described selective inhibitors for LOX-5, LOX-12, and LOX-15, respectively [43–45]. While zileuton at varying concentrations did not seem to affect production of either NO or ROS production by BV-2 cells after LPS stimulation (Fig. 12a, b), both NCTT-956 and PD146176 inhibited ROS/NO production in a concentration-dependent manner (Fig. 12c–f). Similar results were seen when BV-2 cells were stimulated by IFNγ (Additional file 3: Figure S3A–F). These results thus provided information that LPS- and IFNγ-induced ROS and NO in microglial cells may be regulated by LOX-12/15 and not LOX-5.

Fig. 7 ROS production in BV-2 cells after LPS or IFNγ stimulation was inhibited by cPLA2 pharmacological inhibitors or siRNA knockdown. BV-2 cells were starved for 4 h in serum-free DMEM. One hour prior to stimulation, cells were pretreated with the indicated concentrations of cPLA2 inhibitors: a, b AACOCF3 or c, d pyrophenone. Cells were then stimulated with a, c 200 ng/mL LPS or b, d 20 ng/mL IFNγ. Alternatively, BV-2 cells were transfected with siRNA against cPLA2 24 h before being stimulated with e LPS or f IFNγ. For all experiments, ROS production was measured 12 h post-stimulation by CM-H2DCFDA fluorescence as described in the text. Results were expressed as the mean ± SEM (n = 3) and significant difference between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests. **P < 0.01, ***P < 0.001.

Chuang et al. Journal of Neuroinflammation (2015) 12:199
Page 12 of 20
Discussion

cPLA₂ plays a significant role in microglial activation

cPLA₂ has been shown to play a significant role in mediating oxidative/nitrosative and inflammatory responses in neurons, astrocytes, and other cells [46, 47], but less attention has been paid to microglia. The findings of this study clearly demonstrate the involvement of cPLA₂ in LPS- and IFNγ-induced ROS and NO production in microglial cultures. To our knowledge, this is the first study to use primary microglia prepared from cPLA₂ and iPLA₂ knockout mice to provide new evidence for the significant role of cPLA₂ in microglial activation.

The comparison between cPLA₂ knockout and wild-type primary microglia cells showed that cPLA₂ not only plays a crucial role in activating the oxidative/inflammatory pathway, leading to generation and release of ROS/NO, but also to the overall morphological transformation of microglial cells after endotoxin/cytokine stimulation. To ensure that the findings are not a result of alternative mechanisms from long-term functional compensation in response to cPLA₂ knockout, the same conclusion was reached using pharmacological inhibition, with AACOCF3 (non-specific) and pyrrophenone (specific), and RNA interference knockdown in BV-2 cells. Other studies using LPS but not IFNγ as a stimulator support this conclusion in rat primary microglia [30] and BV-2 cells [48]. On the other hand, while iPLA₂ is also constitutively expressed in microglia and a target of AACOCF3, results here with iPLA₂ KO and pharmacological inhibition with BEL showed that this PLA₂ has little role in mediating ROS and NO production in the BV-2 microglial cells. This result is in slight contrast to the prior study by Strokin et al., who suggested that iPLA₂ also contributes to the proinflammatory responses in LPS-treated astrocytes via Ca²⁺ signaling [49]. This difference may well be due to use of different cell type, i.e., microglia versus astrocytes.

The ERK1/2-cPLA₂-ROS-iNOS axis in microglial activation

cPLA₂ is known to have multiple active serine residues susceptible for phosphorylation. Among these serine residues, Ser505 was identified to be phosphorylated by MAPK and served as an important regulator for cPLA₂ activity and subsequent AA release [32, 41]. In the study by Pavicevic with vascular smooth muscle cells, phosphorylation of Ser515 by CaMKII was shown to precede Ser505 phosphorylation and phosphorylation of both Ser515 and 505 sites is required for activation of this enzyme [50]. In primary neurons in culture, stimulation with ionotropic glutamate receptor agonist such as NMDA resulted in ROS production through NADPH oxidase and rapid activation of ERK1/2 and cPLA₂ [31]. In this study, we demonstrated that LPS and IFNγ each mediated a time-dependent increase in phospho-ERK1/2 and cPLA₂ in both primary and BV-2 microglial cells. In both conditions, the time for increase in p-ERK1/2 preceded that for p-cPLA₂. The relationship between p-ERK1/2 and cPLA₂ was further confirmed by U0126, the MEK1/2-ERK1/2 inhibitor, which readily abrogated phosphorylation of cPLA₂.

NADPH oxidase in microglia cells has been shown to play a significant role in neurodegenerative diseases, such as alcohol-induced neurodegeneration [51], Alzheimer’s disease [52], and Parkinson’s disease [53]. Previous study from our laboratory has demonstrated the production of ROS from NADPH oxidase to be upstream of NO production in BV-2 microglia cells. Our studies further demonstrated that in BV-2 microglial cells, LPS and IFNγ can individually stimulate ROS and iNOS/NO through phosphorylation of ERK1/2 [39, 40]. Study by Ribeiro et al. (2013) also demonstrated effects of cannabinoid receptor agonists and antagonists to suppress LPS-induced
microglia activation via ERK1/2, cPLA2, and NF-κB. These results as well as ours placed LPS and IFNγ activation of ERK1/2 and cPLA2 upstream of the NF-κB transcriptional pathway. In rat microglial cells, Szaingurten-Solodkin observed a link between cPLA2 in NADPH oxidase and iNOS activated by aggregated Abeta1-42, a toxic peptide cleaved from the amyloid precursor protein [54]. In their study, it was proposed that cPLA2 regulated NADPH oxidase activity, which in turn caused upregulation of cPLA2, COX-1/2, and iNOS through an NF-κB-dependent mechanism. Taken together, our results with cPLA2 inhibitors as well as siRNA knockdown well demonstrated the role of cPLA2 in mediating ROS and NO production upon stimulation by LPS and IFNγ. Our results with primary microglia isolated from cPLA2 KO brain further validated the link between cPLA2 on ROS and NO production in these cells.

Role of arachidonic acid and LOX in microglial activation

Earlier studies had linked cPLA2 or its downstream metabolites (i.e., AA or lysophospholipids) with ROS production from NADPH oxidase, although the exact mechanism remains to be investigated [55, 56]. In macrophages, there is evidence that cPLA2 can interact directly with NADPH oxidase subunits, namely p47phox and p67phox, which facilitate translocation of these subunits to membranes to form the active NADPH oxidase complex [55, 57]. Alternatively, downstream products of
AA were proposed to be involved in ROS production from NADPH oxidase [58]. Activation of cPLA2 and subsequent release of AA has been shown in the production of an array of eicosanoids, including the production of prostaglandins and leukotrienes through activation of COX and LOX. However, the extent for this action is cell dependent [42]. A number of studies, including those from our own, have demonstrated the increase in PGE2 production upon stimulation with LPS and IFNγ in astroglial cells [59, 60]. In the present study with microglial cells, we showed that while the COX-1/2 inhibitor effectively inhibited LPS- and IFNγ-induced PGE2 production, this condition was not linked to the suppression of ROS and NO production by LPS and IFNγ.

While the action of COX-1/2 is well established in peripheral inflammation and a popular target for non-steroidal anti-inflammatory drugs (NSAIDs), its role in neuroinflammation is not well understood. Aspirin is used after acute stroke not for anti-inflammatory effect but rather for secondary prevention of atherosclerosis due to its antiplatelet properties through inhibition of prostaglandin and subsequent thromboxane A2 [61, 62]. Similarly, numerous recent large-scale double-blind placebo-controlled clinical trials have not found a beneficial effect of COX-1/2 inhibition in the treatment of neurological diseases where neuroinflammation is proposed to be involved, such as Alzheimer’s disease or depression [63, 64]. In agreement with our study, Minghetti and colleagues have also reported that microglial cell
activation increased TNFα and COX-1/2, but this condition did not contribute to ROS/NO production [65, 66].

On the other hand, recent studies have generating growing recognition of LOX in mediating inflammation, and some have implicated its role in neuroinflammation. Lipoxygenases are known to mediate the pathophysiology of numerous inflammatory diseases, including asthma, immune disorders, and cancer. Parallel to the action of COX-1/2 for the biosynthesis of prostaglandins from AA, lipoxygenases mediate the biosynthesis of leukotrienes and eoxins from AA, all of which are eicosa-noids that play a significant role in inflammation and immune function [42]. Of note, the ability for LOX-15 to generate eoxin has been identified as a novel pathway of inflammatory responses in mast cells and eosinophils [67] and as a promising novel target against asthma [68]. Genetic ablation of LOX-12/15, but not LOX-5, was shown to protect against denervation-induced muscle atrophy [69]. In the central nervous system, LOX-12/15 was shown to have increased expression in oligodendrocytes and microglia of periventricular leukomalacia [70], and disease phenotype was ameliorated by absence of LOX-12/15 in animal models of Alzheimer’s disease [71]. The LOX-5 pathway has also been associated with Alzheimer’s disease and other neurodegenerative conditions [72]. Although the mechanism of how LOX causes microglial activation and neuroinflammation remains to be elucidated, our results provided evidence suggesting that LOX activation in microglial cells plays a crucial role leading to induction of ROS and NO. To our knowledge, this is the first finding to biochemically connect cPLA2 pathway to oxidation and inflammatory responses in microglial cells through LOX. Future studies should further examine the specific involvement of LOX isoforms in proinflammatory gene expression and regulation of ROS production in microglial cells.

cPLA2 as a therapeutic target against neurological diseases
Since the 1990s, cPLA2 has been demonstrated to be a favorable target for intervention against a wide range of neurological diseases. Using an experimental stroke model, Bonventre et al. was the first to show that cPLA2 knockout mice suffered less ischemic damage and had smaller infarct volume after transient middle cerebral artery occlusion [21]. Sanchez-Mejia et al. also demonstrated transgenic hAPP mice with cPLA2 knockout to exhibit significantly less cognitive deficit compared with cPLA2 intact transgenic hAPP mice, indicating a potential role of cPLA2 in the pathogenesis of Alzheimer’s disease [73]. AACOCF3, a non-selective cPLA2 and iPLA2 inhibitor, was discovered to be an effective pharmacological...
inhibitor of PLA₂. Due to its physicochemical properties, it can readily penetrate into cell membranes. In thrombin-stimulated platelets, in Ca²⁺ ionophore-stimulated human monocytic cells, and in interleukin 1-stimulated mesangial cells, all liberation of AA is essentially blocked at a concentration of 5 to 20 μM [74, 75]. Since the discovery and popularization of AACOCF³, more recent studies further demonstrated the administration of cPLA₂ pharmacologic

Fig. 12 NO/ROS production by BV-2 cells after LPS stimulation was mitigated by LOX-12/15 inhibition, but not by LOX-5 inhibition. BV-2 cells were serum starved for 3 h followed by 1-h incubation with indicated concentrations of LOX inhibitors: a, b zileuton for LOX-5 inhibition; c, d NCTT-956 for LOX-12 inhibition; and e, f PD146176 for LOX-15 inhibition. The cells were then stimulated with 200 ng/mL LPS. a, c, e NO production was measured in conditioned medium 16 h post-stimulation by Griess protocol. b, d, f ROS production was measured 12 h post-stimulation with CM-H2DCFDA fluorescence. Results were expressed as the mean ± SEM (n = 3), and the significant difference between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests, *P < 0.05; **P < 0.01; ***P < 0.001.
inhibitor to offer protective effect against multiple neurological diseases. This includes the amelioration of focal ischemic damage in experimental stroke [28], prevention of secondary tissue damage in experimental autoimmune encephalitis, an in vivo model for multiple sclerosis [30], as well as preservation of neuronal survival and retention of motor function in a mouse model of spinal cord injury [29, 76].

While most of the studies suggested and focused on the action of cPLA2 in the neurons in the event of neurodegeneration and neuronal apoptosis, less attention was given to the potential role of cPLA2 in the microglia cells. While microglia activation plays an important role to limit neuronal damage and phagocytose cellular debris and foreign pathogens, M1 activation of microglia cells can also promote microglia-induced neuronal damage and further propagate ongoing neuroinflammation. The results of this study had shed light on one potential mechanism of M1 microglia activation, which can potentially be targeted and controlled. Interestingly, inhibition of cPLA2 by AACOCF3 was able to abrogate the morphological changes elicited by LPS and IFN in WT primary microglial cells. We believe that cPLA2 inhibition not only prevents microglia activation but more importantly becomes a viable therapeutic strategy to impede neuronal cell death by limiting secondary neuronal damage. In this regard, inhibiting PLA2 cascade has been considered an essential strategy for opposing microglia activation [77] and discovering new and synthetic inhibitors for PLA2 will be an important future endeavor for understanding and treatment of neurological disorders [78].

Conclusions
This study demonstrated a crucial role of cPLA2 in the activation of microglial cells, specifically in LPS- and IFN-stimulated ROS and iNOS/NO production. In addition, cPLA2 also controls the morphological transformations associated with microglial activation. Upon looking at the downstream pathways, results show that LPS- and IFN-induced activation of ROS/NO depends on LOX-12/15 and not COX-1/2, thus offering new insights into the signaling pathway during microglia activation. Further studies are needed to better understand the molecular mechanisms underlying cPLA2 in microglial activation and how this may offer novel therapeutic options for the prevention and/or treatment of neuroinflammatory/neurodegenerative diseases.

Additional files

Additional file 1: Figure S1. High concentrations of LPS and IFN were toxic to primary microglia at 24 h post-stimulation. Primary microglial cells were treated with various concentrations of either (A) LPS or (B) IFN. Twenty-four hours later, cell viability was measured with the WST-1 protocol as described in the text. Results were expressed as the mean ± SEM (n = 3) and significant difference compared with the control group was determined by one-way ANOVA followed by Dunnett’s post-tests, **P < 0.01, ***P < 0.001.

Additional file 2: Figure S2. cPLA2 protein expression level decreased significantly after siRNA knockdown. Representative blot demonstrating protein levels of cPLA2 and β-actin in BV-2 cells between groups: (1) control, (2) BV-2 cells were transfected with negative control siRNA for 24 h, and (3) BV-2 cells were transfected with siRNA against cPLA2 for 24 h.

Additional file 3: Figure S3. NO/ROS production by BV-2 cells after IFN stimulation was mitigated by LOX-12/15 inhibition, but not by LOX-5 inhibition. BV-2 cells were serum starved for 3 h followed by 1-h incubation with indicated concentrations of LOX inhibitors: (A–B) zileuton for LOX-5 inhibition, (C–D) NCTT-956 for LOX-12 inhibition, and (E–F) PD146176 for LOX-15 inhibition. The cells were then stimulated with 20 ng/mL IFN. (A, C, E) NO production was measured in conditioned medium 16 h post-stimulation by Griess protocol. (B, D, F) ROS production was measured 12 h post-stimulation with CM-H2DCFDA fluorescence. Results were expressed as the mean ± SEM (n = 3) and significant difference between the respective groups was determined by one-way ANOVA followed by Dunnett’s post-tests, *P < 0.05, ***P < 0.001.

Competing interests
The authors have declared that there are no competing interests.

Authors’ contributions
DYC and GYS provided the concepts, designed the experiments, and drafted the manuscript. DYC carried out the experiments and analyzed the data. DYC performed genotyping of mice and isolation of primary microglia. PTK provided the iPLA2 KO mice. AS and ZG contributed significantly to the drafting of the manuscript. All authors have read, edited, and approved the final manuscript.

Acknowledgements
We would like to express our appreciation for (1) Dr. Joseph V. Bonventre for providing the cPLA2 transgenic animals; (2) Yijia Zong for helping establish the protocol to isolate primary microglia from transgenic mice brains; (3) the Mouse Genetics Core in Washington University School of Medicine for assisting with the husbandry and genotyping for the iPLA2 transgenic animals used in this study; and (4) the Cellular Immunology Core in the University of Missouri for aiding in the flow cytometry protocol.

Funding
This publication was made possible by NIH Grants 2P01 AG08357 from NIA and P01AT006273 from the National Center for Complementary and Alternative Medicines (NCCAM), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI), and NS074350 from the National Institute of Neurological Disorders and Stroke (NINDS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIA, NCCAM, ODS, NCI, NINDS, or the National Institutes of Health.

Author details
1Interdisciplinary Neuroscience Program, University of Missouri, Columbia, MO, USA. 2Center for Translational Neuroscience, University of Missouri, Columbia, MO, USA. 3Center for Botanical Interaction Studies, University of Missouri, Columbia, MO, USA. 4Department of Biochemistry, University of Missouri, Columbia, MO, USA. 5Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. 6Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, USA.

Received: 23 August 2015 Accepted: 21 October 2015

Published online: 31 October 2015

References
1. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6161):156–61. Epub 2013/01/12.
2. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76(2):77–98.
8. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. J Neuroimmunol. 2011;231(1):39–46.
9. Nehezi II, Nenslezyk U, Zhao, AW, Bal-Price A, Tolkovsky AM, Brown GC. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol. 2011;186(8):4973–83.
10. Franco R, Fernandez-Suarez D. Alternatively activated macrophages and microglia in the central nervous system. Prog Neurobiol. 2013;113:65–86.
11. Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2015.[Epub ahead of print]
12. Hu X, Leak RK, Shi Y, Suengua J, Gao Y, Zheng P, et al. Microglial and macrophage polarization-new prospects for brain repair. Nat Rev Neurol. 2015;11(1):56–64.
13. Pan J, Jin JL, Ge HM, Yin KL, Chen X, Han LJ, et al. Malbaltot A regulates microglia M1/M2 polarization in experimental stroke in a PAFα-receptor-dependent manner. J Neuroinflammation. 2015;12:51.
14. Xie CY, Zhang S, Gao Y, Wang ZZ, Chen NH. Selective modulation of macrophage polarization to M2 phenotype for stroke treatment. Int Immunopharmacol. 2015;25(2):377–82.
15. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43(11):3063–70.
16. Wang G, Zhang J, Hu X, Zhang L, Mao L, Jiang X, et al. Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J Cereb Blood Flow Metab. 2013;33(12):1864–74.
17. Wang G, Shi Y, Jiang X, Leak RK, Hu X, Wu Y, et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSKbeta/PTEN/akt axis. Proc Natl Acad Sci U S A. 2015;112(39):E5833–43.
18. Brown GC. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans. 2007;35(Pt 5):1119–21.
19. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biological Chemistry. 2006;281(30):21628–36.
20. Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, et al. Characterization of phenotype markers and neurotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70–85.
21. Hanisch UK. Microglia as a source and target of cytokines. Glia. 2002;40(1):40–55.
22. Sheng W, Zong Y, Mohammad A, Aijt D, Cui J, Han D, et al. Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA2-IA expression in astrocytes and microglia. J Neuroinflammation. 2012;9:90.
23. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res. 2009;50(Suppl):S327–42. Epub 2011/11/18.
24. Leslie CC. Cytosolic phospholipase A2: physiological function and role in disease. J Lipid Res. 2015; Epub 2015/04/04.
25. Bonventre JV, Huang Z, Taiher MR, O’Leary E, Li E, Moskowitz MA, et al. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997;390(6660):622–6. Epub 1997/12/24.
26. Nagase T, Uozumi N, Ishi S, Kita Y, Yamamoto H, Ohga E, et al. A pivotal role of cytosolic phospholipase A2(β) in bleomycin-induced pulmonary fibrosis. Nat Med. 2002;8(5):480–4. Epub 2002/05/02.
27. Nagase T, Uozumi N, Ishii S, Kume K, Iizumi T, Duchi Y, et al. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2(β). Nat Immunol. 2003;4(1):42–6. Epub 2001/03/23.
28. Kishimoto K, Li KU, Chang J, Klaus JA, Kibler KK, Dore S, et al. Cytosolic phospholipase A2 α amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice. J Neuroinflammation. 2010;7:42. Epub 2010/08/03.
29. Tai N, Kuwabara K, Kobayashi M, Yamada K, Ono T, Seno K, et al. Cytosolic phospholipase A2 α, an alpha inhibitor, pyrophosphate, displays anti-arthritic and anti-bone destructive action in a mouse arthritic model. Inflamm Res. 2010;59(1):153–62. Epub 2009/08/06.
30. Rachel L, Berger S, Hadad N, Kachko L, Karter M, Szaingurten-Solodkin I, et al. Reduction of cPLA2α overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis. Eur J Immunol. 2006;38(10):2905–15. Epub 2008/10/01.
different cell types in the central nervous system. Mol Neurobiol. 2014;50(1):116–14. Epub 2014/02/28.
48. Ribeiro R, Wen J, Li S, Zhang Y. Involvement of ERK1/2, cPLA2 and NF-kappaB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 2013;100:101–114. Epub 2012/12/12.
49. Smolkin M, Sergeeva M, Reiser G. Proinflammatory treatment of astrocytes with lipopolysaccharide results in increased Ca2+ signaling through increased expression of Vipophospholipase A2 (PLA2). Am J Physiol Cell Physiol. 2011;300(3):C542–9.
50. Pavicevic Z, Leslie CC, Malik RJ. PLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells. J Lipid Res. 2008;49(4):74–37. Epub 2008/01/12.
51. Qin L, Crews FT. NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration. J Neuroinflammation. 2012;9:5.
52. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, et al. Activation of NADPH oxidase in Alzheimer’s disease brains. Biochem Biophys Res Commun. 2002;293(1):5–9.
53. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase inhibition of oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2003;100(10):145–50.
54. Szaingurten-Solodkin I, Hadad N, Levy R. Regulatory role of cytosolic phospholipase A2alpha in NADPH oxidase activity and in inducible nitric oxide synthase induction by aggregated Abeta1-42 in microglia. Glia. 2009;57(16):1727–40. Epub 2009/05/21.
55. Shmelzer Z, Haddad N, Admon E, Persich L, Leto TL, Eitan-Hazan Z, et al. Unique targeting of cytosolic phospholipase A2 to plasma membranes mediated by the NADPH oxidase in phagocytes. J Cell Biol. 2003;162(4):683–92. Epub 2003/08/13.
56. Dana R, Leto TL, Malech HL, Levy R. Essential requirement of cytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem. 1998;273(1):441–5. Epub 1998/02/07.
57. Zhao X, Bey EA, Wientjes FB, Cathcart MK. Cytosolic phospholipase A2 (cPLA2) regulation of human monocyte NADPH oxidase activity: cPLA2 affects translocation but not phosphorylation of p67(phox) and p47(phox). J Biol Chem. 2002;277(28):25385–92. Epub 2002/07/09.
58. Levy R, Lowenthal A, Dana R. Cytosolic phospholipase A2 is required for the activation of the NADPH oxidase associated H+ channel in phagocyte-like cells. Exp Med Biol. 2000;479:125–35. Epub 2000/07/18.
59. Xu J, Weng YI, Simonyi A, Krugh BW, Liao Z, Weisman GA, et al. Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachidonic acid release in primary murine astrocytes. J Neurochem. 2002;83(2):259–70. Epub 2002/11/09.
60. Xu J, Yu S, Sun AV, Sun GY. Oxidant-mediated AA release from astrocytes involves PLA2(R) and PLA2(Y). Free Radic Biol Med. 2003;34(12):1531–43.
61. Antithrombotic TC. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71.
62. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287–90.
63. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis. 2012;27(4):405–13. Epub 2012/07/10.
64. Trepanier CH, Milgram NW. Neuroinflammation in Alzheimer’s disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? J Alzheimers Dis. 2010;21(4):889–99.
65. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neurochem Exp Neurol. 2004;68(3):901–5. Epub 2004/09/30.
66. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Sub-Cellular Biochem. 2007;42:127–41. Epub 2007/07/07.
67. Feltenmark S, Gautam N, Brunstrom A, Griffiths W, Backman L, Edensiu C, et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipooxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci U S A. 2005(10):6803–5. Epub 2005/01/11.
68. Sachs-Olsen C, Sanak M, Lang AM, Gielicz A, Mowinckel P, Lodrup Carlsen KC, et al. Eoxins: a new inflammatory pathway in childhood asthma. J Allergy Clinical Immunol. 2010;126(4):859–67. e9. Epub 2010/10/06.
69. Bhattacharya A, Hamilton R, Jemigan A, Zheng Y, Sabia M, Rahman MW, et al. Genetic ablation of 12/15-lipooxygenase but not 5-lipooxygenase protects against denervation-induced muscle atrophy. Free Radic Biol Med. 2014;67:30–41.
70. Haynes RL, van Leyen K. 12/15-lipooxygenase expression is increased in oligodendrocytes and microglia of periventricular leukomalacia. Dev Neurosci. 2013;35(2–3):140–54.
71. Yang H, Zhuo JM, Chu J, Chinnici C, Pratico D. Amelioration of the Alzheimer’s disease phenotype by absence of 12/15-lipooxygenase. Biol Psychiatry. 2010;68(10):922–9.
72. Joshi YB, Pratico D. The 5-lipooxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease phenotype. Front Cell Neurosci. 2014;8:346.
73. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Nat Neurosci. 2008;11(11):1311–8. Epub 2008/10/22.
74. Gronich J, Konieczkowski M, Gelt MH, Nemencoff RA, Sedor JB. Interleukin 1 alpha causes rapid activation of cytosolic phospholipase A2 by phosphorylation in rat mesangial cells. J Clin Invest. 1994;93(3):1224–33.
75. Farooq AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmaco. Rev. 2005;45(1):391–602.